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Among primary headaches, cluster headache is certainly the
most painful and unbearable, particularly for the patients
suffering from its chronic form. It is characterized by attacks
of unilateral periorbital, frontal and/or temporal pain asso-
ciated with ipsilateral autonomic signs (ptosis, miosis, con-
junctival injection, tearing, rhinorrhoea, nasal congestion).
Its episodic form is characterized by bouts (clusters) of
weeks or months, separated by headache-free intervals of
variable length (months or years), but in chronic cluster
headache (CCH), which affects almost 10% of patients, the
attacks persist for at least 1 year without remission, or with
remissions lasting less than 1 month [1]. These patients often
require one or more preventive drugs for relief, such as ste-
roids, verapamil, lithium carbonate and methysergide.
Unfortunately, about 1% of CCH patients become refractory
to all existing pharmacological treatments.
In fact, suffering from intractable CCH is an atrocious
condition, which affects every aspect of the patients’ lives,
and may even push some of them to commit suicide as the
ultimate desperate solution to avoid pain.
Thus, it is imperative for headache clinicians and
researchers, to test any possible remedy to this condition by
invasive and non-invasive surgical procedures when phar-
macological remedies have failed.
Over the years, many such procedures have been used,
such as radiofrequency lesions, glycerol injections or bal-
loon compressions of the gasserian ganglion, gamma knife
surgery or root section of the trigeminal nerve, trigeminal
tractotomy, lesions of the nervus intermedius or greater
superficial petrosal nerve, blockade or radiofrequency
lesions of the pterygopalatine ganglion, and microvascular
decompression of the trigeminal nerve combined with
nervus intermedius section [2]; none of these have dis-
played satisfactory long-term results.
In addition, when neuromodulation methods were first
applied with success in some cases of intractable CCH [3],
they immediately had a great resonance in the scientific
community and aroused great hope in affected patients.
The neuromodulation techniques used up to now are deep
brain stimulation (DBS) of the ventro-posterior hypothal-
amus [3–6] and occipital nerve stimulation [7, 8]. Obser-
vational studies of hypothalamic DBS (hBDS) seemed to
report slightly better results, but also more serious side
effects, culminating in fatal cerebral haemorrhage in one
patient. Because of this potential risk of hDBS procedures,
it is of uttermost importance to carefully select CCH
patients to whom hDBS will be proposed and to provide
evidence-based proof of its clinical efficacy.
Criteria defining drug-resistant chronic cluster headache
(iCCH) patients are based on experts’ opinion and widely
accepted [9, 10]. The consensus is that patients cannot be
considered drug-resistant unless drugs known to be effec-
tive in cluster headache and belonging to at least three
different pharmacological classes have been administered
at a sufficient dose and for a sufficient time.
In two studies [5, 6], attack recurrence at varying delays
was described when the stimulator was switched off or
when the battery ran flat, suggesting that the clinical effect
was probably not due to the natural history of the disorder.
Since the stimulation is not perceived by the patient, these
observations also do not favour a placebo effect, although
they cannot rule it out [11]. A placebo-controlled study was
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thus urgently needed, and Fontaine et al. deserve praise for
organizing and completing such a trial embracing a sub-
stantial number of patients [12].
The study by Fontaine et al., the first controlled trial for
hDBS in CCH, was a multicenter double-blind study con-
ducted on 11 patients, who after the electrode implantation
were randomized to a ‘‘switch on’’ or a ‘‘switch off’’
condition [12]. This ‘‘randomized phase’’ consisted in a
cross-over trial, where in the first month, a group of
patients received effective stimulation and another group
‘‘sham’’ stimulation, whereas in the second month the
stimulators of the first group were switched off and those of
the second group switched on. These two periods were
separated by a week of ‘‘wash-out’’. The randomized phase
was followed by a 1-year open phase, during which every
patients received effective hypothalamic stimulation.
In the randomized phase, no significant effect was found
for hDBS in comparison with sham stimulation, whereas
the open phase confirmed the good results obtained in
previous open-labelled studies, i.e. C50% reduction of
attack frequency in about 60% of patients.
The data obtained from the randomized phase, therefore,
provide no evidence favouring the use of hDBS in drug-
resistant CCH patients, which contrasts with the longer
open-label phase and previous studies. This discrepancy
may have several explanations. The most relevant one is
probably the rather short, 1-month, duration of the treatment
periods in the randomized phase. Hypothalamic DBS, like
occipital neurostimulation, is likely to act by slow neuro-
modulatory processes which take time to have an effect.
Although in previous studies some patients had rapid
improvement after hDBS, significant beneficial effect was
delayed in many others, and it is the rule in occipital nerve
stimulation. This may explain why patients who did not
respond in the randomized phase of the trial became
responders in the subsequent open-label phase after a longer
duration of stimulation. Unfortunately, the authors were not
able to provide stronger evidence for the beneficial effect in
the open phase by switching the stimulators off, since the
patients to whom a second longer randomized phase was
proposed did not accept the risk of being allocated to the
‘‘off’’ arm and losing the treatment effect. On the other
hand, the patients who were implanted in Fontaine et al.’s
study are not totally comparable to those included in most
open studies. In the latter, intractability was defined on the
basis of stricter criteria including treatment failure to at least
four different classes of preventive drugs [9], while in this
controlled trial patients were included if they had failed (or
not tolerated) only two medications, verapamil and lithium.
Admittedly, less refractory patients might in theory respond
better to hypothalamic stimulation, which would have
increased the likelihood of a favourable outcome, and
intractability may not be irreversible as found in another
study [6] where even patients considered to be intractable
went into remission while on a waiting list for DBS. The
problem is merely an ethical one, as the international con-
sensus is that hDBS, which is not a riskless procedure,
should be restricted to patients who resist to all available
non-invasive preventive treatments.
In conclusion, this first randomized controlled study of
hDBS unfortunately fails to provide level I evidence for
this procedure in drug-resistant chronic cluster headache,
as no significant effect was found during the randomized
1-month phase. Thanks to the good efficacy found in the
open-label phase, however, it supports the favourable
results from previous observational studies and confirms
that most (60%), though not all, patients can be signifi-
cantly improved by the procedure.
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